Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry
Authors:
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 69 (4) , 158-166
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Bayer HealthCare
- World Heart Federation
- Abbott Laboratories
This publication has 21 references indexed in Scilit:
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2012
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Characteristics and Outcome of Patients Hospitalised for Lower Extremity Peripheral Artery Disease in France: The COPART RegistryEuropean Journal of Vascular and Endovascular Surgery, 2010
- Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosisEuropean Heart Journal, 2010
- Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health RegistryEuropean Heart Journal, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- External Validity of Clinical Trials in Acute Myocardial InfarctionArchives of internal medicine (1960), 2007
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2006
- The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study designAmerican Heart Journal, 2006
- External validity of randomised controlled trials: “To whom do the results of this trial apply?”The Lancet, 2005